Skip to main content

BACE1 regulates expression of Clusterin in astrocytes for enhancing clearance of β-amyloid peptides



Abnormal accumulation of amyloid beta peptide (Aβ) in the brain induces a cascade of pathological changes in Alzheimer’s disease (AD), and inhibiting BACE1, which is required for Aβ generation, is therefore being explored for the treatment of AD by reducing Aβ accumulation. As Bace1 knockout mice exhibit increased number of reactive astrocytes and AD brains have reactive astrocytes that surround amyloid plaques, we investigated the role of BACE1 in astrocytes and determined whether BACE1 regulates astrocytic functions.


We conducted unbiased single cell RNA-seq (scRNA-seq) using purified astrocytes from Bace1 KO mice and wild type control littermates. Similar scRNA-seq was also conducted using AD mice with conditional deletion of Bace1 in the adult stage (5xFAD;Bace1fl/fl;UBC-creER compared to 5xFAD;Bace1fl/fl controls). We compared the transcriptomes of astrocyte and reactive astrocyte clusters and identified several differentially expressed genes, which were further validated using Bace1 KO astrocyte cultures. Mice with astrocyte-specific Bace1 knockout in 5xFAD background were used to compare amyloid deposition. Mechanistic studies using cultured astrocytes were used to identify BACE1 substrates for changes in gene expression and signaling activity.


Among altered genes, Clusterin (Clu) and Cxcl14 were significantly upregulated and validated by measuring protein levels. Moreover, BACE1 deficiency enhanced both astrocytic Aβ uptake and degradation, and this effect was significantly attenuated by siRNA knockdown of Clu. Mechanistic study suggests that BACE1 deficiency abolishes cleavage of astrocytic insulin receptors (IR), and this may enhance expression of Clu and Cxcl14. Acutely isolated astrocytes from astrocyte-specific knockout of Bace1 mice (Bace1 fl/fl;Gfap-cre) show similar increases in CLU and IR. Furthermore, astrocyte-specific knockout of Bace1 in a 5xFAD background resulted in a significant attenuation in cortical Aβ plaque load through enhanced clearance.


Together, our study suggests that BACE1 in astrocytes regulates expression of Clu and Cxcl14, likely via the control of insulin receptor pathway, and inhibition of astrocytic BACE1 is a potential alternative strategy for enhancing Aβ clearance.


Typical clinical symptoms of Alzheimer’s disease (AD) are gradual loss of memory and cognitive ability, likely resulting from amyloid deposition and neurofibrillary tangles in the patients’ brains [1,2,3]. BACE1 is identified as Alzheimer’s β-secretase for initiating production of β-amyloid peptides (Aβ) from amyloid precursor protein (APP), and oligomeric or aggregated Aβ is viewed as the major pathogenic protein causing amyloid deposition and senile plaques [4]. Inhibition of BACE1 is, therefore, pursued for treating AD patients [5]. As demonstrated in clinical trials, BACE1 inhibition is effective for reducing brain Aβ levels [6]. However, BACE1 inhibitors have failed in the trials due to lack of cognitive benefit [7,8,9]. This is in line with reports that reveal critical roles of neuronal BACE1 in the control of synaptic transmission [10], proper organization of hippocampal mossy fiber infrapyramidal bundle [11], and regulation of synaptic plasticity such as long term potentiation (LTP) from Schaffer collateral-CA1 synapses and in mossy fiber-CA3 synapses [12,13,14,15,16]. Bace1 KO mice also exhibit deficits in myelination and neurogenesis, as well as schizophrenia-like behaviors and seizures [17].

Considering the fact that abnormal accumulation of Aβ leads to amyloid deposition, which is associated with pathological events including the intraneuronal tau hyperphosphorylation and formation of neurofibrillary tangles [18, 19], it becomes important to understand how to properly inhibit BACE1 activity and to avoid neuronal side effects. We have previously shown that deletion of Bace1 in the adult mice removes pre-existing amyloid plaques [15], implying the potential upregulation of clearance machinery, which is most likely mediated by glia cells. BACE1 is also expressed by astrocytes [20, 21], and germline Bace1 deficiency induces astrogenesis during mouse early development [22]. The role of BACE1 in astrocyte function in the context of AD however remains to be explored. Hence, we aimed to determine the role of BACE1 in astrocytes by utilizing the generated Bace1 global and conditional knockout mice.

We purified astrocytes from 2-month-old Bace1 KO mouse brains and conducted single cell sequencing (scRNA-seq). Deletion of Bace1 in astrocytes increased the percentage of reactive astrocytes when compared to wild type (WT) littermates. Genes related to Aβ clearance, including Clusterin (Clu), were significantly increased in Bace1 deficient astrocytes. We confirmed that this upregulation of Clu in Bace1-null astrocytes also resulted in an increase at the protein level in astrocytes from global and astrocyte-specific deletion of BACE1. Downregulation of CLU partially reversed the effect of Bace1 deletion on astrocytic clearance of Aβ. Mechanistically, we show that astrocytic BACE1 deficiency results in an increase in insulin receptor (IR) and downstream P38 and ERK1/2 signaling pathways, which may regulate transcription of the Aβ clearance-related genes. Astrocyte specific-knockout of Bace1 (Bace1fl/fl;Gfap-cre) resulted in similar increases in both CLU and IR. Furthermore, astrocyte specific-knockout of Bace1 crossed with 5xFAD (5xFAD;Bace1fl/fl;Gfap-cre) resulted in a significant attenuation of total cortical Aβ plaque load without affecting Aβ generation. Together, this suggests that astrocytic inhibition of BACE1 may contribute to a enhanced amyloid clearance and might provide an alternative therapeutic pathway that avoids off-target effects associated with significant inhibition of neuronal BACE1.


Deletion of Bace1 in astrocytes alters transcriptomic profiles of reactive population

To understand the role of BACE1 in astrocytes, we enriched astrocytic cell population from 3 brains of wild-type (WT) and Bace1 KO mice at 2-months of age using astrocyte-cell specific antigen 2 (ACSA2) immunomagnetic beads. Purified astrocytes were subjected to 10 × Genomic single cell RNA sequencing and initial read count analysis by Cell Ranger (10 × Genomics). Overall gene number, read counts, and mitochondrial RNA appeared to be similar between all samples (Supplemental Figure S1A). Approximately 17,000 cells were identified for each genotype. Using Seurat R package (Version 4, Satija lab), we analyzed the sequencing results and clustered these cells into UMAP-defined clusters (Fig. 1A). Different cell clusters were arranged based on the unique gene signature as previously described [23, 24]: 1) major populations of non-reactive astrocytes [indicated by high Atp1b2 expression and low Vimentin (Vim) expression], 2) reactive astrocytes (high Atp1b2 and high Vim), 3) microglia [Cluster of differentiation 68 (CD68)], 4) oligodendrocytes [Myelin and lymphocyte protein (Mal)], 5) oligodendrocyte precursor cells (OPC) [Platelet-derived growth factor receptor A 2 (Pdgfr2) or Chondroitin sulfate proteoglycan 4 (CSPG4)], and 6) endothelial cells [Platelet endothelial cell adhesion molecule (PECAM1)] (Fig. 1B). From UMAP-defined clusters, it appeared that Cluster 0, 2, and 6 were non-reactive astrocytes while Clusters 3, 4, 8, and 10 were reactive astrocytes (Fig. 1B and Supplemental Figure S1B). As expected, astrocytes represented the majority of cells, and approximately 20% of remaining cells were identified as oligodendrocytes (ochre; Clusters 1 and 5), and OPCs (teal; Cluster 7 and 12). Although in low abundance, microglia (in cluster 9 in blue) and endothelial cells (cluster 7 in fuchsia) were present (Fig. S1B).

Fig. 1
figure 1

BACE1 deficiency enhances reactive astrocyte population. A Total Uniform manifold approximation and projection (UMAP) clustering of ACSA2 + positive cells from derived from 2-month old Bace1-null and WT mice via single-cell RNA-seq, N = 3 samples, ~ 17,000 cells per genotype. Clusters are labeled by each cell type. B Violin plot representation of log2 fold change gene expression of known cell type gene markers and correlated with labeled clusters. C Proportion of indicated cell types. Comparison of average proportion of each cell types from each samples genotype (* p-value < 0.05, ** p-value < 0.01). Two-way ANOVA with Sidak multiple comparison post-test. D UMAP of only astrocyte clusters after removing other cell types. R Astrocytes refer reactive astrocytes while Non-R Astrocytes refer to non-reactive astrocytes. E Western blot of primary astrocytes cultures lysates derived from Bace1-null and WT mice to confirm increase in reactive astrocytes from Bace1-null mice. GFAP antibody was used for detecting GFAP levels, while actin was for loading controls. F GFAP levels were quantified based on Western blot band intensity normalized to actin (N = 3, ** p-value < 0.01, Student t-test)

After using known brain cell type markers to filter out non-astrocyte cells [23, 25], we re-clustered and compared gene profiles derived from Bace1-null and WT astrocytes. Quantification showed that reactive astrocytes comprised approximately 20% of total cells in Bace1−/− brains compared to only ~ 10% reactive astrocytes in Bace1+/+ controls (Fig. 1C). Correspondingly, the proportion of non-reactive astrocytes in WT controls was greater, while other cell populations were not significantly altered under this immune-panning condition (Fig. 1C). Furthermore, BACE1 deficiency visibly increased numbers of reactive astrocytes (labeled as R Astrocytes in teal, Fig. 1D).

Consistent with this unbiased result, we found that GFAP protein levels in lysates from BACE1 deficient primary astrocyte cultures were significantly higher compared to WT controls (Fig. 1E and F), further indicating that BACE1 deficiency promotes astrocytes in the reactive states.

Comparing the transcriptomes of pan reactive astrocytes from Bace1 KO and WT mice using Seurat V4, we identified 37,658 unique gene signatures, with about 610 significantly differentially expressed genes (DEGs) (adjusted p-value < 0.05, log2FC > 0.2; Supplemental Table 1). A volcano plot revealed many significant DEGs (Fig. 2A). Among these genes, we found several genes known to have roles in synaptic maintenance, clearance of β-amyloid peptides (Aβ), glutamate homeostasis, metabolism, hippocampal synaptogenesis, insulin and insulin growth factor signaling and AP-1 transcription factor family (Table 1 and Supplemental Table 1). Expectedly, Bace1 from Bace1 KO reactive astrocytes was also significantly reduced.

Fig. 2
figure 2

Germline BACE1 deficiency results in unique reactive astrocyte transcriptomes. A Top differentially expressed genes comparing Bace1-null to WT reactive astrocyte transcriptomes expressed as a volcano plot of log2 fold change value gene expression and –log10(p-value), Wilcoxon ranked sum test was used to calculate p-values. Dotted lines indicate DEG cut-offs for |log2(fold change)|> 0.2 and -log10 (p-value) of 1.3, corresponding to p-value < 0.05. Green triangle highlights elevated expression of Clu and Cxcl14. Blue dots highlight genes that are members of the AP-1 transcription machinery (B) Violin plot of genes of interest, Clu, and Cxcl14, expression comparing Bace1-null and WT reactive astrocyte clusters (* p-value < 0.05, *** p-value < 0.001; Wilcoxon ranked sum test was used to calculate p-value). C Distribution of cells highly expression Clu and Cxcl14. Scale indicates gene expression levels. D Western blotting of genes of interest – Clu and Cxcl14 – in primary astrocyte culture lysates with or without 2 μM of aggregated Aβ42 treatment. E Quantification of Western blot band intensity normalized to actin with or without Aβ42 treatment (N = 3, * p-value < 0.05, ** p-value < 0. *** p-value < 0.001; One-way ANOVA with Sidak post-test)

Genes thought to regulate clearance of Aβ, marked in green triangles, received our particular attention. We showed that Clu and C-X-C Motif Chemokine Ligand 14 (Cxcl14) expression levels were significantly elevated in Bace1-null reactive astrocyte gene clusters (Fig. 2B and C). These changes were then further validated on the protein level. Western blot analysis showed that both CLU and CXCL14 protein levels were increased in Bace1-null primary astrocytes, both basally and when stimulated with Aβ, compared to WT astrocytes (Fig. 2D-E).

Deletion of Bace1 in 5xFAD mice enhances expression of Clu and Cxcl14

As previously mentioned, conditional knockout of BACE1 in the adult reverses previously formed amyloid plaques in adult 5xFAD;Bace1fl/fl; UBC-creER compared to non-BACE1 deleted 5xFAD;Bace1fl/fl adult mice [15]. To understand the role that adult BACE1 deficiency might play on astrocyte transcriptomes in adult mice with the 5xFAD background, we compared scRNA-Seq of astrocytes from 14-month old 5xFAD;Bace1fl/fl; UBC-creER and 5xFAD;Bace1fl/fl mice. Overall gene number, read counts, and mitochondrial RNA appeared to be similar between all samples (See Supplemental Figure S2). About 7,000 astrocytes were recovered from these mice after magnetic activated cell sorting (MACS) by ACSA2 immunomagnetic beads and cell type filtration. When comparing reactive astrocyte population transcriptomes from 5xFAD;Bace1fl/fl; UBC-creER and 5xFAD;Bace1fl/fl mice, 1,873 DEGs (P < 0.05) were noted (Supplemental Table 2). Among these DEGs, insulin degrading enzyme (IDE), klotho (Kl) and lysosomal associated membrane protein 2 (LAMP2) were upregulated in the 5xFAD;Bace1fl/fl; UBC-creER compared to 5xFAD;Bace1fl/fl mice. Furthermore, we once again found significantly elevated Clu and Cxcl14 gene expression in the reactive astrocyte population (Fig. 3A), and an increase in the number of Cluhigh and Cxcl14high astrocytes in the case of 5xFAD;Bace1fl/fl; UBC-creER mice (Fig. 3B).

Fig. 3
figure 3

Bace1 deficiency in adult mice increases Clu and Cxcl14 gene expression in reactive astrocytes. A Transcriptomic analysis was performed on single-cell RNA-seq of astrocytes sorted from 14-month-old 5xFAD;Bace1fl/fl and 5xFAD;Bace1fl/fl;UBC-creER mice (N = 3, per genotype). Violin plot of genes showed high expression of Clu and Cxcl14 (log2 fold change expression) in 5xFAD;Bace1fl/fl; UBC-creER compared 5xFAD;Bace1fl/fl reactive astrocyte clusters. B Distribution of cells highly expressing Clu and Cxcl14 with indicated log2 fold change scaling based on UMAP clustering of astrocytes

Our data suggest that both germline and adult BACE1 deficiency increases a group of astrocytes that commonly express more Cxcl14 and Clu. These Cluhigh and Cxcl14high reactive astrocytes are likely capable of clearing more β-amyloid peptides (Aβ) as higher levels of CLU are known to increase Aβ clearance [26, 27].

BACE1 deficiency increases uptake and degradation of Aβ by astrocytes

Since BACE1 deficiency altered astrocytic transcriptomic profiles, we then asked whether astrocytes with BACE1 deficiency would enhance Aβ clearance, which might contribute to the reversal of pre-formed amyloid plaques in 5xFAD mice with deletion of Bace1 in the adult as previously reported [15]. We cultured primary astrocytes from WT and Bace1-null mice, and then treated these cultured astrocytes with aggregated oligomeric human Aβ42 according to the published procedure [28]. We found that BACE1 deficient astrocytes had visibly increased uptake of HiLyte Fluor-555-labeled Aβ42 (Anaspec, Fremont, CA) after 12 hrs incubation compared to WT controls (Fig. 4A). High magnification images showed that the majority of the HiLyte Fluor-555-labeled Aβ42 signal was found within astrocyte cell bodies (Fig. 4A, inset). Quantification showed that enhanced uptake of aggregated Aβ42 began at around 6 hrs post incubation and plateaued at around 12 hrs, while it took about 36 hrs for WT astrocytes to uptake about the same amount of HiLyte Fluor-555-labeled Aβ42 (Fig. 4B).

Fig. 4
figure 4

BACE1 deficiency enhances astrocytic clearance of Aβ in vitro. A Confocal imaging of astrocyte primary cultures from BACE1-null and WT perinatal mice pups and treated with 2 μM of Aβ42 tagged with fluorescent Hilyte-555 for indicated incubation times. Stained with phalloidin (green) to mark F-actin and ToPro3 (blue) to mark nuclei. Scale bars represents 10 μm. Inset shows magnified image of Aβ42 within phalloidin marked astrocyte boundaries. B Quantification of Aβ42 integrated fluorescence within phalloidin marked astrocyte boundaries and normalized to number of nuclei and astrocyte area (N = 6, * p-value < 0.05, ** p-value < 0.01; One way ANOVA, with Tukey post testing comparing between time points. C Western blot of astrocyte primary culture lysates from indicated genotypes and treated with 2 μM of aggregated Aβ42 for the indicated incubation times. Images indicate major bands for BACE1, Aβ42 (human, oligomeric), and actin. D Quantification of Western blot Aβ42 band intensity normalized to actin (N = 3, * p-value < 0.05, One-way ANOVA, with Tukey post testing comparing between samples)

We also examined Aβ levels by Western blot. Although the levels of oligomeric Aβ42 in Bace1-null astrocytes were higher than that in WT controls during initial incubation (12 to 36 h), significantly less Aβ42 was found at the time of 72 hrs (Fig. 4C). This was further confirmed by multiple replication experiments (Fig. 4D), indicating that BACE1 deletion likely also enhanced degradation of oligomeric Aβ42 after initial uptake. In line with previous reports [20, 21, 29], astrocytes treated with Aβ42 appeared to enhance expression of BACE1 (Fig. 4C), suggesting that elevated BACE1 in AD brains might have vicious inhibitory effect on astrocytic Aβ clearance.

Clusterin contributes to enhanced Aβ uptake in Bace1-null astrocytes

Because CLU is known to regulate Aβ clearance and degradation and elevation of the CLU protein level was evident, we chose to examine whether elevated CLU levels would contribute to enhanced Aβ uptake and degradation in Bace1-null astrocytes. To this end, we identified that one well-characterized siRNA (Santa Cruz Biotechnology) was able to reduce CLU protein levels in primary astrocytes in a dose dependent manner, with astrocytes treated with 80 pmol of Clu siRNA down-regulated about 48.6% expression of CLU (Supplemental Figure 3A and B).

We then pretreated Bace1-null and WT astrocytes with 80 pmol of Clu or control siRNA before treating astrocytes with aggregated Aβ42 and examined intracellular Aβ levels by either Western blot (Fig. 5A and B), or fluorescently tagged Aβ by confocal imaging (Fig. 5C). We showed that knocking down Clu in Bace1-null astrocytes reduced the uptake of Aβ42, when compared to Bace1-null astrocytes treated with control siRNA (Fig. 5).

Fig. 5
figure 5

Clusterin underlies astrocyte endocytosis of Aβ in vitro. A Western blot of Bace1-null and WT-primary astrocytes pretreated with either 80 pmol of Clu siRNA or 80 pmol of control scrambled siRNA and incubated with 2 μM of Aβ42 for indicated times. Images indicate major bands for Aβ42 (human, oligomeric) and GAPDH. B Quantification of Western blot Aβ42 band intensity normalized to actin (N = 3, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001; One-way ANOVA with Tukey post testing comparing between samples. C Confocal imaging of astrocyte primary cultures from BACE1-null and WT and pretreated with either Clu or control scrambled siRNA then treated with 2 μM of Aβ42 tagged with fluorescent Hilyte-555 for indicated incubation times. Stained with phalloidin (green) to mark F-actin and ToPro3 (blue) to mark nuclei. Scale bars represents 10 μm

Further quantification showed a clear shift in the uptake pattern (Fig. 5B): slowed uptake of Aβ42 by astrocytes when CLU levels were reduced, and treatment with Clu siRNA reduced total levels of Aβ42 in both Bace1-null and WT astrocytes from 0.5 to 36 hrs compared to control siRNA treated astrocyte (Fig. 5B). Confocal images also showed delaying uptake of Aβ42 when comparing Bace1-null astrocytes with and without specific Clu siRNA treatment (Fig. 5C).

Altogether, these results add evidence that CLU indeed plays a direct role in astrocytic clearance of Aβ. Furthermore, it suggests that increased CLU levels underlie the increased uptake of Aβ in Bace1-null astrocytes.

BACE1 deficiency increases P38, ERK1/2 and cJun activity

In order to investigate signaling pathways responsible for the increased expression of Clu and other aforementioned DEGs in BACE1 deficient astrocytes, we performed a database search using BioMart to determine common transcription factors for these DEGs. Members of the activated protein 1 (AP-1) transcription family were the most commonly found elements to be related to DEGs of BACE1 deficient astrocytes, including Cxcl14 and Clu. Furthermore, some members of the AP-1 family themselves were DEGs upregulated in BACE1 deficient reactive astrocytes (Fig. 2B, Table 1, and Supplemental Table 1). AP-1 activation is known to be modulated by upstream molecules such as P38, JNK1/2, and ERK1/2 [30, 31]. We found that the levels of JNK were not significantly changed, but levels of phosphorylated P38, Jun, and ERK1/2 were significantly elevated in Bace1-null astrocyte cultures (Fig. 6A); total Jun and P38 levels were not obviously changed. Quantification of replicated results confirmed this in Fig. 6B.

Fig. 6
figure 6

BACE1 deficiency enhances P38, ERK1/2, and cJun phosphorylation. A Western blot of BACE1-null and WT primary astrocytes lysates. Images indicate major bands for pJun, total Jun, pP38, total P38, pERK1/2, pJNK and Calnexin. B Quantification of pJun/total cJun, pP38/total p38, and pERK1/2 band intensity normalized to Calnexin (N = 3, * p-value < 0.05, One-way ANOVA with Tukey post testing comparing between samples)

Our results imply that BACE1 deficiency in astrocytes results in an increase of pP38 and pERK1/2 activation, which then phosphorylates and activates downstream Jun and AP-1 mediated transcription of its downstream molecules such as Clu, which is related to enhanced astrocytic clearance of Aβ.

BACE1 deficiency increases astrocytic insulin receptor signaling

We further explored how BACE1 deficiency would activate the aforementioned signaling molecules in astrocytes. It was previously reported that insulin receptor (IR) is a BACE1 cleavage substrate in the liver [32], and insulin signaling regulates both P38 and ERK1/2 MAPK activity. Furthermore, some DEGs of the insulin and insulin growth factor families were altered in Bace1-null astrocytes (Table 1 and Supplemental Table 1). IR is composed of a heterodimer dimer, α and β subunits, and the membrane anchored β subunit is identified as a BACE1 substrate. When Bace1 is deleted, the IRβ subunit is no longer cleaved and more preserved IRβ subunit might be available for enhancing P38 and ERK1/2 activity. We therefore investigated whether BACE1 deficiency might also enhance astrocytic insulin receptor availability.

Western blot analysis revealed that BACE1 deficiency significantly reduced levels of BACE1-cleaved IRβ C-terminal fragment (CTF) in Bace1-null astrocytes compared to their WT controls (Fig. 7A), consistent with prior results that BACE1 deficiency abrogated cleavage of IRβ in astrocytes. An increase of total mature IRα and IRβ levels was also noted, while as well as a much larger increase in the phosphorylated IRβ (pIRβ) subunit (Fig. 7A), which is required for downstream activation for pP38 and ERK1/2 MAPK. Quantification of replicated results confirmed changes of these proteins (Fig. 7B). Altogether, this suggests that astrocytic BACE1 regulated IR receptor availability by cleavage in a manner similar to liver BACE1 and IR.

Fig. 7
figure 7

BACE1 deficiency preserves astrocytic IR bioavailability. A Western blot of Bace1-null and WT primary astrocytes culture lysates. Images indicate major bands for IRβ, IRβ CTF, pIRβ, IRα, and actin. B Quantification of IRβ, IRβ CTF, pIRβ, and IRα band intensity normalized to actin (N = 4, * p-value < 0.05, ** p-value < 0.01, One-way ANOVA with Tukey post testing comparing between samples. C Western blot of BACE1-null primary astrocytes culture lysates treated with 1 μM of BMS-754807 or control. Images indicate major bands for CLU, CXCL14, and actin. D Quantification of IRβ, IRβ CTF, pIRβ, and IRα band intensity normalized to actin (N = 4, * p-value < 0.05, One-way ANOVA with Tukey post testing comparing between samples)

We further tested whether insulin signaling might be responsible for the elevated CLU and CXCL14 levels in Bace1-null astrocytes. Since insulin is already present in the G-5 supplemented astrocyte media, we inhibited insulin signaling by using BMS-754807 (SelleckChem), a potent IR tyrosine kinase phosphorylation inhibitor (Fig. 7C and D). BMS-754807 treatment resulted in a potent reduction of both CLU and CXCL14 levels in Bace1-null astrocytes (Fig. 7C). Quantification of replicated results confirmed changes of these proteins (Fig. 7D). This suggests that elevated CLU and CXCL14 levels in Bace1-null astrocytes is dependent on IR signaling.

Altogether, this suggests that astrocytic BACE1 regulated IR availability by cleavage in a matter similar to liver BACE1 and IR and that IR signaling may play a role in reactive astrocyte amyloid clearance.

Targeted deletion of Bace1 in astrocytes increases astrocytic levels of IR, CLU and CXCL14

To investigate whether in vivo astrocytic BACE1 deficiency results in increased IR, CLU and CXCL14, we bred Bace1fl/fl mice with Gfap-cre mice [Tg-Gfap-cre 73.12Mvs, the Jackson lab] and examined Bace1fl/fl;Gfap-cre mice, which conditionally deleted  Bace1 mostly in astrocytes due to expression of Cre recombinase by the mouse Gfap promoter [33]. To avoid potential effects from other Gfap-expressing lineage cells, we isolated astrocytes from 2-month old Bace1fl/fl;Gfap-cre mice using ACSA2+ immunobeads and the purified ACSA2 + astrocytes were used for Western blot (Fig. 8).

Fig. 8
figure 8

Targeted astrocytic deletion of Bace1 enhances IR bioavailability and downstream amyloid clearance proteins. A Western blot of ACSA2 + astrocyte enriched lysates from Bace1fl/fl;Gfap-cre and Bace1fl/fl mice. Images indicate major bands for IRβ, IRβ CTF, CLU, CXCL14, and actin. B Quantification of indicated protein intensity normalized to actin (N = 3, * p-value < 0.05, One-way ANOVA with Tukey post testing comparing between samples)

We found that astrocytes from Bace1fl/fl;Gfap-cre mice had an increased amount of mature IRβ and reduced IRβ CTF compared to Bace1fl/fl astrocytes in a manner similar to above in vitro conditions (comparing Fig. 7 and 8). We also found a significant increase in CLU and CXCL14 protein levels (Fig. 8). Altogether, this suggests that BACE1 deficiency increases astrocytic IR signaling and its downstream molecule CLU and CXCL14 in a mostly cell autonomous manner both in vivo and in vitro.

Bace1 deletion in astrocytes decreases amyloid plaque levels

To further understand the effect of astrocytic Bace1 deletion on amyloid pathology, we bred Bace1fl/fl;Gfap-cre with 5xFAD;Bace1fl/fl mice to generate 5xFAD;Bace1fl/fl;Gfap-cre and 5xFAD;Bace1fl/fl mice for comparison. We used P75 female mice from each genotype, as female 5xFAD mice show less variations in amyloid pathology [34]. Thioflavin-S staining of fixed brain sections revealed an overall less amyloid depositions in 5xFAD;Bace1fl/fl;Gfap-cre mouse brains compared to 5xFAD;Bace1fl/fl mouse controls (Supplemental Figure 4). In an enlarged view, it was clear that less Aβ plaques were formed in the 5xFAD;Bace1fl/fl;Gfap-cre cortex compared to controls (Fig. 9A), and was confirmed by quantification (Fig. 9B). Although, levels of Aβ plaques appeared to be reduced in the subiculum and hippocampus of 5xFAD;Bace1fl/fl;Gfap-cre mice, further quantification showed that this decrease in hippocampus was, overall, not significant (Fig. 9B).

Fig. 9
figure 9

Targeted astrocytic deletion of Bace1 reduces amyloid plaques by increasing Aβ clearance. A Thioflavin-S staining of amyloid plaques from saggital brain sections of 5xFAD;Bace1fl/fl;Gfap-cre and 5xFAD;Bace1fl/fl. Scale bar indicates 100 µm (B) Quantification of Thioflavin-S positive amyloid plaques calculated by counting serial sagittal sections, which were selected at 10-section intervals (N = 7 for 5xFAD;Bace1fl/fl;Gfap-cre and 5xFAD;Bace1fl/fl). C Western blot of cortical lysates from 5xFAD;Bace1fl/fl;Gfap-cre and 5xFAD;Bace1fl/fl mice. Images indicate APP full length, APP C-terminal C99 (detected by 6E10) and C99/C83 bands (detected by APP A8717 antibody). Actin was included as loading control

We also examined the effect of astrocytic BACE1 on total amyloid processing and generation by Western blot (Fig. 9C). We found that total levels of full length APP, C99, and C83 cleavage substrates appeared to be unchanged across cortical samples. This most likely indicates that brain Aβ levels are mainly resulted from neuronal sources while the contribution of astrocytic Aβ levels are minimal. It is noted that neurons have higher levels of BACE1 and APP than glial cells. Most likely, astrocytic BACE1 deletion induced IR signaling and increased CLU levels, which contribute to the enhanced glial Aβ clearance.


BACE1 is a type I transmembrane aspartyl protease, which mainly cleaves membrane bound proteins such as amyloid precursor protein (APP), type I and type III neuregulin and Sez6L [35, 36]. Since its discovery, BACE1 studies have mostly focused on the role of BACE1 in neurons including amyloid production, myelination, and synaptic function [5, 10,11,12, 14, 16, 36]. Furthermore, BACE1 inhibitors used in clinical trials have largely failed due to lack of efficacy and because of neuronal side effect from global BACE1 inhibition [5, 10, 37, 38]. In contrast, relatively few studies reveal the unique role of BACE1 in astrocytes, despite known expression of BACE1 in reactive astrocytes and its contribution to astrocyte development [20, 22]. We provided the first evidence that astrocytic BACE1 regulates astrocytic Aβ clearance by promoting more beneficial astrocytes in the reactive state, and inhibition of astrocytic BACE1 might be a novel target for future AD therapies, which can contribute to the reduction of Aβ deposition.

In this study, we conducted unbiased single cell RNA-seq experiments and compared transcriptomic profiles in mouse brain astrocytes, with or without BACE1. We provided evidence that BACE1 deficiency increases a population of reactive astrocytes expressing higher levels of genes such as Clu, which are known to enhance clearance of aggregated Aβ. Cultured astrocytes with BACE1 deficiency showed an increase in Aβ clearance and degradation, suggesting that targeted inhibition of BACE1 or specific downstream pathways in astrocytes may likely be beneficial for AD treatment. Furthermore, we found evidence that astrocytic IR, a potential BACE1 cleavage substrate, and downstream pathways might contribute to astrocytic expression of astrocytic clearance genes both in vitro and in an astrocyte specific BACE1 deficiency mouse model.

In AD development of brains, astrocytes are activated and reactive astrocytes are often found surrounding amyloid plaques. Reactive astrocytes contribute to amyloid clearance, directly by endocytosis [39] or producing amyloid degrading enzymes [40, 41], and indirectly by preventing amyloid aggregation [42, 43] or enhancing clearance by other cell types [44, 45]. However, as AD pathology progresses, reactive astrocytes not only experience a loss of amyloid clearance efficiency, but may also play a role in promoting neuroinflammation and toxicity [46]. Furthermore, genetic descriptions of various disease-related astrocyte subtypes [25, 47, 48] have made it clear that an unbiased, single cell genetic approach is key to understanding how astrocyte subtypes contribute to neurological diseases. To this end, we used single cell RNA-seq to compare various astrocyte clusters from BACE1 deficient mice. In comparing Bace1-null and wild type mice, we found an increase in reactive astrocyte clusters, which is in line with the previous observation showing increased astrocyte genesis and reactivity in the Bace1-null mice [22]. When comparing the transcriptomes of individual UMAP defined astrocyte clusters between Bace1-null and wild type mice, a variety of known AD-related DEGs were noted (Fig. 2B and Supplemental Table 1). Among these upregulated DEGs from Bace1-null reactive astrocytes, Clu gained our particular attention, because it is highly expressed in astrocytes, is a top GWAS risk factors for the development of AD, and has a known role in clearance of aggregated Aβ [49,50,51,52]. Cxcl14 was another highly expressed DEGs on the list, although total number of Cxcl14 expressing cells was relatively low. CXCL14 is chemokine with known roles in peripheral inflammation, but is less explored in the CNS or in the field of neurodegeneration. However, GWAS indicates that two SNPs near the Cxcl14 locus is associated with increased tau and p-tau [53]. We validated that both of these two genes were elevated in cultured Bace1-null primary astrocytes compared to WT controls (Fig. 2D). Intriguingly, CLU and CXCL14 levels appeared to be increased with Aβ42 treatment (Fig. 2D). In 14-month old 5xFAD;Bace1fl/fl; UBC-creER mice, elevation of these proteins were also prominent compared to 5xFAD;Bace1fl/fl (Fig. 3A).

To understand the effect of BACE1 deficiency on amyloid clearance, we conducted in vitro experiments to compare astrocytes cultured from WT and Bace1-null mice to avoid the inference from other cell types. An increase of fluorescence-labeled Aβ42 uptake by Bace1-null astrocytes for the first 12 hrs was clearly more obvious than control astrocytes. With the consistently detected elevation of CLU in Bace1-null astrocytes, we asked whether CLU levels would affect uptake of the fluorescence-labeled Aβ42 in Bace1-null astrocytes. Clu knockdown resulted in decreased uptake by both Bace1-null and WT astrocytes, suggesting that higher level of CLU correlates with more uptake of Aβ42. Interestingly, Clu siRNA treatment in Bace1-null astrocytes still had slightly more uptake of Aβ42 than Clu siRNA-treated WT astrocytes, and this observation indicates that other BACE1- regulated genes in astrocytes may also contribute to enhanced uptake of Aβ42.

Our validated finding is in line with the published observation regarding the beneficial effect of CLU on astrocytic uptake and degradation of Aβ42 [26, 27]. CLU is also found to enhance brain endothelial vascular clearance of Aβ42 by protecting against AD associated metabolic stress, glutamate toxicity, and synaptic dysfunction [54, 55]. We further explored how BACE1 deficiency alters CLU levels, and our mechanistic study implied that CLU elevation is likely related to astrocytic insulin receptor (IR) signaling. IR has α and β subunits and its β subunit (IRβ) was previously identified as a BACE1 substrate in the liver [32]. We found that BACE1-cleaved C-terminal fragment (CTF) of IRβ was reduced on the western blot by BACE1 deficiency. In Bace1−/− astrocytes, full length IRβ is consistently higher both in cultured astrocytes and with astrocyte specific knockout for BACE1, detectable even without γ-secretase inhibition. This elevation of full length IRβ and reduced IRβ CTF is attributable to abrogated cleavage by BACE1 (Fig. 7 and 8). The availability of more functional IRs on the surface of astrocytes of BACE1 deficient astrocytes would most likely explain the elevation of phosphorylated IRβ, and its downstream signaling molecules P38, ERK1/2, and Jun (Fig. 6). We also discovered upregulation of several members of the AP-1 transcription factors in BACE1-null astrocytes (Supplemental Table 1 and Fig. 2B), similar to changes seen in deletion of Bace1 in microglia [56]. Although total protein levels of several AP-1 transcription factors were not increased in BACE1-null astrocytes, interestingly, we found increased phosphorylation of Jun (Fig. 6), indicating an upregulation of its transcription activity. Consequently, these transmitted signals will enhance AP-1 mediated transcription of Clu. The enhancement of insulin signaling has been pursued in AD clinical trials for purported benefits in adult neurogenesis and synaptic function as well.

To understand whether the effects of BACE1 inhibition on astrocytic pathways and Aβ clearance was astrocyte specific or due to cell–cell communication in vivo, we generated an astrocytic BACE1 knockout model (Bace1fl/fl;Gfap-cre). In astrocytes acutely extracted from Bace1fl/fl;Gfap-cre mice, we saw similar increases in mature IR, reduced IR CTF, increased CLU, and increased CXCL14 in a manner similar to previous in vitro results (Fig. 8). Importantly, we also found that astrocytic BACE1 deficiency reduces cortical Aβ load in a 5xFAD mouse background (5xFAD;Bace1fl/fl;Gfap-cre), without altering total Aβ generation in vivo (Fig. 9), but rather via Cxcl14high and Cluhigh astrocytes. In a pilot observation from small numbers of mice, amyloid plaques in 10-month old of 5xFAD;Bace1fl/fl;Gfap-cre were not obviously reduced when compared to 5xFAD;Bace1fl/fl controls, likely due to more predominant effects of available BACE1 in neurons and microglia. We have recently shown that deletion of Bace1 in microglia appears to have a strong effect on removing amyloid deposition [57], and Aβ is continuingly produced from neurons.


We describe a model of BACE1 inhibition that enhances astrocytic clearance of Aβ, most likely in a cell-specific and autonomous manner, by increasing insulin signaling, which in turn upregulates expression of Aβ clearance genes such as Clu (see graphic illustration in Fig. 10). Increasing BACE1 levels in AD reactive astrocytes is likely to cause a vicious cycle that may block an efficient astrocytic clearance of Aβ. Hence, specific inhibition of BACE1 in astrocytes may be an alternative strategy for reducing Aβ in human AD therapy that is worthy of further exploration in future.

Fig. 10
figure 10

Schematic diagram illustrates BACE1 deficiency in astrocytes and its effect on the astrocytic function. BACE1 deficiency decreases cleavage of astrocytic inulin receptor (IR). This abrogated cleavage, compared to wild type astrocytes, in turn leads to gain of function of insulin receptor signaling to its downstream molecules such as P38 and ERK1/2. This increased MAPK pathway activates AP-1 transcription to elevate Clu levels, and to enhance amyloid endocytosis by BACE1-null reactive astrocytes

Materials and methods

Mouse strains and breeding strategy

Astrocyte specific Bace-1 deletion was achieved by breeding Tg-Gfap-cre, Gfap specific Cre expressing mice (73.12Mvs, JAX stock#012,886, the Jackson Laboratory) with Bace-1 conditional mice (Bace-1 fl/fl), carrying loxP-flanked genes as previously described [15]. The resulting Bace1fl/+;Gfap-cre mice were crossed with Bace1fl/fl mice to obtain a colony with the following genotype: Bace1fl/fl;Gfap-cre. Bace1fl/fl;Gfap-cre mice were maintained by breeding with Bace-1 fl/fl. Female Bace1fl/fl;Gfap-cre mice were also crossed with male 5xFAD;Bace1 fl/fl resulting in 5xFAD;Bace1fl/fl;Gfap-cre mice. Various age groups of 5xFAD;Bace1fl/fl;Gfap-cre and 5xFAD;Bace1fl/fl females were used for downstream Western blot and amyloid staining due to reported inconsistencies in male 5xFAD amyloid pathology [34].

Adult conditional knockout Bace1fl/fl;UBC-CreER and 5xFAD;Bace1fl/fl;UBC-CreER were bred and maintained as previously described [15]. All lines were routinely backcrossed with C57BL/6 J mice for at least five generations to ensure consistent genetic background for phenotypic analyses. BACE1-null mice were obtained by heterozygous breeding of Bace1+/- males and females (Jax stock# 004,714, Jackson Lab) as previously described.

All experimental protocols were approved by the Institutional Animal Care and Use Committee of the Lerner Research Institute and University of Connecticut Health Center in compliance with the guidelines established by the Public Health Service Guide for the Care and Use of Laboratory Animals.

Adult mouse astrocyte isolation

Astrocytes were isolated from mouse brains using adult brain dissociation kit (MiltenyiBiotec, 130–107-677) for single-RNA sequencing (see below), as well as isolating astrocytes from Bace1fl/fl;Gfap-cre and Bace1fl/fl. Briefly, mice were perfused with 25 mL of PBS and forebrains were isolated and transferred to gentleMACS Dissosciator (Milltenyi) to form a single-cell suspension. Subsequently, myelin, cell debris, and erythrocytes were removed and remaining cells were immunolabelled with ACSA2 immunomagnetic beads (cat. No. 130–097-678). The cell suspension was passed though magnetic columns and QuadroMACS separators, which retained ACSA2-positive cells on the column. This ACSA2 immunomagnetic bead MACS method is reported to be less disruptive to glial cell processes and reactivity than microfluidic systems such as FACS [58].

Single-cell RNA sequencing

For single cell RNA-sequencing, ACSA2 positive astrocytes from littermate controlled 2-month-old Bace1-null and WT mice. 3 separate samples per group (2 males, 1 female) were submitted for downstream analysis. Astrocytes from 3 pooled brains (2 males, 1 female) from 14-month old 5xFAD;Bace1fl/fl;UBC−creER and 5xFAD;Bace1fl/fl mice were also submitted for scRNA seq. Astrocytes were checked for cell number and viability. Samples with little debris and > 80% viability were then used for single cell RNA sequencing (University of Connecticut Single Cell Genomics). About 12,000 cells of each sample type were loaded onto 10X Chromium Single Cell RNA sequencing chips. Sample mRNAs were barcoded and subsequently converted into cDNA. After cDNA library quality inspection, libraries were sequenced using an Illumina Novaseq 6000 sequencer. Custom CellRanger pipeline (University of Connecticut Single Cell Genomics) provided initial UMI counts and tSNE clustering. Raw scRNA-seq data will be provided to the NIH Gene expression Omnibus (GEO) for open-source use.

The data analysis was taken into consideration of a published guidance [24]. For secondary analysis, the Seurat version 4 packaged in R (Satija lab) was used to determine differential gene expression using normalized read counts for identifiable genes, reclustering, displaying violin plots of gene expression, and mapping gene expression in cells. For violin and dimension plots of gene expression, scaling excludes outlier cells below 5th or above 95th percentile of range.

Quality control parameters were set to only include cells with greater than 1,000 identifiable genes, less than 25,000 read counts, and less than 20% mitochondrial RNA. Filtered samples were then grouped by genotype and read counts were normalized and transformed using SCTransform (Supplementary Figures 1 and 2) PCA dimensional reduction was followed by UMAP clustering. Identified reactive astrocyte cluster transcriptomes were then compared with a log normalized scaling factor of 100,000 in order to generate a number of differentially expressed genes, with low overall expression. DEG adjusted p-values are presented as p-values for analysis.

Primary perinatal astrocyte culture and isolation

Primary astrocytes cultures were prepared from littermate controlled perinatal mouse pups resulting from Bace1+/- X Bace1+/- breeding. Pups were genotyped at P0 (see below) and then primary mixed glia were prepared from P1-3 as described previously [59, 60]. Briefly, brain tissue was isolated from skulls, bisected, and then incubated with 0.25% trypsin at 37 °C for 15 min, with occasional gentle swirling. Afterwards, tissue solution was gently triturated with fire-polished glass pipettes and passed through a 70 micron filter to form a single-cell suspension. The mixed glia culture was cultured in a T75 flask in DMEM-F12 containing 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, and 1% penicillin/streptomycin (Life Technologies) for 12–14 days. Mixed glia cultures were split twice with 4–5 day intervals to achieve a pure mature astrocyte culture.

Astrocytes were seeded 1 × 106 onto 6 well plates for Western blot purpose, and 1 × 104 for 8 well chamber sides for confocal staining. Media was switched to DMEM-F12 medium containing 1% serum-free G5 astrocyte media supplement (Gibco) for 12–24 hrs before treatment. Cells were maintained and grown in a humidified atmosphere of 5% CO2 at 37 °C.

Preparation of aggregated Aβ42

Non-tagged Aβ42 peptide (ThermoFisher) and fluorescent Hilyte 555 tagged- Aβ42 (Anaspec) were prepared according to previous reports [28]. Briefly, peptides were solubilized in 0.1% NH4OH containing 0.01% (w/v) NaN3, and further re-suspended in DMEMF12 (pH 7.4) and stored at -20 °C. Prior to use, peptides were oligomerized by incubation with constant rotation for 24 hrs at 4 °C. Formation of beta-sheets was detected by Thioflavin-T fluorescence indicating the formation of aggregated Aβ42 (data not shown). Cells were treated with 2 μM of aggregated Aβ42 for 36 hrs for most experiments, except for Western blotting of phosphorylated signaling pathways, in which cells were treated with Aβ42 for 4 hrs or otherwise indicated.

Clusterin siRNA knockdown

Knockdown of Clu in astrocyte cultures was attained by using Clusterin siRNA reagents (Santa Cruz Biotechnology, catalog no. sc-43689) or control scrambled siRNA (Santa Cruz Biotechnology, catalog no. sc-37007) according to manufacturer’s instructions. Briefly, siRNA plasmids were combined with siRNA transfection medium and duplexed with siRNA transfection media. Astrocyte specific G-5 media was removed and replaced with siRNA duplexed transfection solution for 6 hrs. Afterwards transfection solution was replaced with astrocyte specific G-5 media.

For determining correct dosage, cells were incubated with 10, 20, 40 or 80 pmol of Clu siRNA or 80 pmol of Ctrl siRNA, before switching to astrocyte media. After 72 hrs in astrocyte media, cells were lysed and probed for CLU expression. After optimization, cells were treated with 80 pmol of Clu or Ctrl siRNA before treatment with aggregated Aβ42 either untagged (Western blot) or tagged with HiLyte 555 (Cytochemistry imaging).

Western blotting

Astrocytes from perinatal culture or acutely isolated from adult mice were washed with ice-cold PBS and then were lysed in RIPA lysis buffer containing 50 mM Tris–HCl (pH 7.4), 1 mM EDTA, 100 mM NaCl, 0.1% SDS, 1 mM PMSF, 1 mM sodium orthovanadate, 1 μg/ml leupeptin, 1 μg/ml pepstatin, and 10 μg/ml aprotinin, for 10–30 min at 4 °C with rotation. The lysate was collected and further bath sonicated on ice for 30 sec on and off cycles at 60 Hz for 5 min and then centrifuged at 15,000 × g for 30 min at 4 °C. Total brain lysates were sonicated by drill sonicator in RIPA buffer before centrifugation. Protein concentrations were determined using a BCA assay kit (Pierce). Equal amounts of protein from each sample were loaded and electrophoretically resolved on 4%–12% SDS-PAGE (NuPAGE system, Life Technologies) gels with MOPS or MES running buffer (Thermofisher). After electrophoresis, proteins were transferred to nitrocellulose membranes at 100 V for 2 hrs. The membranes were washed with PBS with 1:2,000 20% Tween-20 and blocked with 1% bovine serum albumin (BSA) and 0.5% evaporated milk for 1 hr at room temperature. The membranes were probed with primary antibody (see table for antibody list), followed by incubation with appropriate secondary HRP-conjugated antibody (1:2,000). The antibody-bound proteins were detected by an iBright 1500 imaging system (Invitrogen). To ensure equal loading, the blots were reprobed with monoclonal anti-actin (1:10,000) or calnexin (1:1,000). For quantification purposes, band intensities of immunoblots were analyzed using imageJ software. For phosphorylated antibodies, membranes were washed and blocked in Tris-Buffered Saline with 1:2,000 of 20% Tween-20 and blocked in 5% BSA.

Cytochemistry imaging

After treatments with aggregrated HiLyte Fluor-555-labeled Aβ42 (Anaspec, Fremont, CA), astrocytes were washed with 3 times with PBS for 5 min, before fixation with 4% formaldehyde for 10 min at room temperature, and permeabilization with 0.1% TritonX-100 for 5 min. After careful washing, cells were incubated with 100 nM of Alexaflour 488 phalloidin (Thermofisher A12379) and Topro3 (Thermofisher T3605) diluted in 1% BSA/PBS for 10 min at room temperature. Cells were washed then mounted on coverslips with 90% glycerol, 20 mM Tris–HCL (1 M, pH 8.8), and 0.5% (w/v) p-Phenylenediamine (CSHB Protocol). Images were captured with either a Leica TCS-SP8-AOBS or Zeiss LSM 800 Confocal microscope.

Images were quantified with ImageJ software. Integrated density of HiLyte Fluor-555-labeled Aβ42 fluorescence intensity with the bounds of a mask based upon phalloidin defined maximum threshold was measured and normalized to phalloidin mask area and nuclei marked by ToPro3.

Quantification of amyloid plaque load

Quantification of amyloid plaques was conducted with serial sagittal sections, which were selected at 10-section intervals. Amyloid plaques were labeled with 0.05% Thioflavin-S. Images were captured by BZ-X800 microscope (Keyence) using a 2 × objective and stitched together with the Keyence stitching module. Total plaque numbers in the cerebral cortex and hippocampus (including subiculum) were counted using ImageJ software (National Institutes of Health). Seven female 5xFAD;Bace1fl/fl ;Gfap-cre and six female 5xFAD;Bace1fl/fl mice in each age group were used.

Genotyping primers

Primer Target

Sequence (5’- > 3’)

APPSwFlLon – common


APPSwFlLon – mutant reverse


APPSwFlLon – wild type reverse


Bace1 – forward


Bace1 mutant




Gfap-cre forward


Gfap-cre reverse


Loxp forward


Loxp reverse


UBC-creERt2 forward


UBC-creERt2 reverse


Antibody list used for the study

Antibody Name

Catalog no



Actin (Clone AC-15)




APP C-terminal








Amyloid Beta (Oligomer), A11



ThermoFisher Scientific

BACE1 (D10E5)



Cell Signaling




Cell Signaling




Cell Signaling

Clusterin-a (B-5)



Santa Cruz








Santa Cruz

IRβ (CT-3)



Santa Cruz

Jun (60A8)



Cell Signaling

P38 (D13E1)



Cell Signaling

pP38 (Thr180/Tyr182)



Cell Signaling

pIRβ (10C3)



Santa Cruz




Cell Signaling

pErk1/2 (Thr202/Tyr204)



Cell Signaling

pJNK (Thr183/Tyr185)



Cell Signaling




Santa Cruz

Statistical analysis

Bar graph results are expressed as mean ± SD. Fold change values and p-values for scRNA seq comparison were based on Wilcoxon Ranked Sum test generated by Seurat. The statistical analyses were performed using GraphPad Prism 6.0 software (GraphPad Software, San Diego). Student’s t-tests were used to compare between 2 groups. Two-way ANOVAs were used to compare multiple groups, post-test of Sidak, Bonferonni, or Tukey was used to compare between different groups. Differences with *p < 0.05, **p < 0.01, ***p < 0.001 were considered significant. (Table 1).

Table 1 Differentially expressed genes in Bace1-deleted astrocytes

Availability of data and materials

All original data presented in the paper will be made available for reviews when needed. Research materials will be also made available when it is required. The GEO entry for the scRNA seq data: GSE230116.



Amyloid precursor protein


β-site APP cleaving enzyme


Amyloid peptides


Glial fibrillary acidic protein


apolipoprotein E




C-X-C Motif Chemokine Ligand 14


Insulin receptor


C-terminal fragment


Single cell RNA sequencing


T-Distributed Stochastic Neighbor Embedding


Mitogen-activated protein kinase


Jun proto-oncogene


38 KDa mitogen-activated protein kinases


Extracellular signal-regulated kinases




Insulin-degrading enzyme


Lysosomal associated membrane protein-2




  1. Corriveau RA, et al. Alzheimer’s Disease-Related Dementias Summit 2016: National research priorities. Neurology. 2017;89(23):2381–91.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Golde TE. Alzheimer’s disease - the journey of a healthy brain into organ failure. Mol Neurodegener. 2022;17(1):18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Jack CR Jr, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol. 2014;13(3):319–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. McDade E, et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol, 2021;17(11):703–14.

  7. Egan MF, et al. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease. Alzheimers Res Ther. 2019;11(1):68.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Sur C, et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain. Brain. 2020;143(12):3816–26.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Novak G, et al. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimers Res Ther. 2020;12(1):58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Das B, et al. BACE1 controls synaptic function through modulating release of synaptic vesicles. Mol Psychiatry, 2021;26(11):6394–410.

  11. Ou-Yang MH, et al. Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Sci Transl Med. 2018;10(459):eaao5620.

    Article  PubMed  Google Scholar 

  12. Wang H, et al. BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J Neurosci. 2008;28(35):8677–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wang H, et al. Mossy fiber long-term potentiation deficits in BACE1 knock-outs can be rescued by activation of alpha7 nicotinic acetylcholine receptors. J Neurosci. 2010;30(41):13808–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lombardo S, et al. BACE1 partial deletion induces synaptic plasticity deficit in adult mice. Sci Rep. 2019;9(1):19877.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hu X, et al. BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. J Exp Med. 2018;215(3):927–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhu K, et al. Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function. Biol Psychiatry. 2018;84(7):478–87.

    Article  CAS  PubMed  Google Scholar 

  17. Hampel H, et al. The β-Secretase BACE1 in Alzheimer’s Disease. Biol Psychiatry. 2021;89(8):745–56.

    Article  CAS  PubMed  Google Scholar 

  18. McDade E, et al. The informed road map to prevention of Alzheimer Disease: A call to arms. Mol Neurodegener. 2021;16(1):49.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhao J, O’Connor T, Vassar R. The contribution of activated astrocytes to Aβ production: implications for Alzheimer’s disease pathogenesis. J Neuroinflammation. 2011;8:150.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Chacón-Quintero MV, et al. Beta-Secretase 1 Underlies Reactive Astrocytes and Endothelial Disruption in Neurodegeneration. Front Cell Neurosci. 2021;15: 656832.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hu X, et al. BACE1 regulates hippocampal astrogenesis via the Jagged1-Notch pathway. Cell Rep. 2013;4(1):40–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Tasic B, et al. Shared and distinct transcriptomic cell types across neocortical areas. Nature. 2018;563(7729):72–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wang M, et al. Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application. Mol Neurodegener. 2022;17(1):17.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Bettens K, et al. Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. Mol Neurodegener. 2015;10:30.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Wojtas AM, et al. Astrocyte-derived clusterin suppresses amyloid formation in vivo. Mol Neurodegener. 2020;15(1):71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Stine WB, et al. Preparing synthetic Aβ in different aggregation states. Methods Mol Biol. 2011;670:13–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Bettegazzi B, et al. β-Secretase activity in rat astrocytes: translational block of BACE1 and modulation of BACE2 expression. Eur J Neurosci. 2011;33(2):236–43.

    Article  PubMed  Google Scholar 

  30. Herdegen T, Waetzig V. AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration. Oncogene. 2001;20(19):2424–37.

    Article  CAS  PubMed  Google Scholar 

  31. Raivich G, Behrens A. Role of the AP-1 transcription factor c-Jun in developing, adult and injured brain. Prog Neurobiol. 2006;78(6):347–63.

    Article  CAS  PubMed  Google Scholar 

  32. Meakin PJ, et al. The beta secretase BACE1 regulates the expression of insulin receptor in the liver. Nat Commun. 2018;9(1):1306.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Garcia AD, et al. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat Neurosci. 2004;7(11):1233–41.

    Article  CAS  PubMed  Google Scholar 

  34. Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dislich B, et al. Label-free Quantitative Proteomics of Mouse Cerebrospinal Fluid Detects beta-Site APP Cleaving Enzyme (BACE1) Protease Substrates In Vivo. Mol Cell Proteomics. 2015;14(10):2550–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Hampel H, et al. The β-Secretase BACE1 in Alzheimer's Disease. Biol Psychiatry. 2020;89(8):745–56.

  37. Das B, Yan R. A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment. CNS Drugs. 2019;33(3):251–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Yan R. Physiological Functions of the beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2. Front Mol Neurosci. 2017;10:97.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wyss-Coray T, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med. 2003;9(4):453–7.

    Article  CAS  PubMed  Google Scholar 

  40. Vekrellis K, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000;20(5):1657–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Dorfman VB, et al. Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer’s disease. Neurobiol Aging. 2010;31(10):1743–57.

    Article  CAS  PubMed  Google Scholar 

  42. Matsubara E, et al. Apolipoprotein J and Alzheimer’s amyloid β solubility. Biochem J. 1996;316(2):671–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Nuutinen T, et al. Amyloid-β 1–42 induced endocytosis and clusterin/apoJ protein accumulation in cultured human astrocytes. Neurochem Int. 2007;50(3):540–7.

    Article  CAS  PubMed  Google Scholar 

  44. Nelson AR, Sagare AP, Zlokovic BV. Role of clusterin in the brain vascular clearance of amyloid-β. Proc Natl Acad Sci U S A. 2017;114(33):8681–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ries M, Sastre M. Mechanisms of Aβ Clearance and Degradation by Glial Cells. Front Aging Neurosci. 2016;8:160.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Perez-Nievas BG, Serrano-Pozo A. Deciphering the Astrocyte Reaction in Alzheimer’s Disease. Front Aging Neurosci. 2018;10:114.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Soreq L, et al. Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of Human Brain Aging. Cell Rep. 2017;18(2):557–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Boisvert MM, et al. The Aging Astrocyte Transcriptome from Multiple Regions of the Mouse Brain. Cell Rep. 2018;22(1):269–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Harold D, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1088–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Lambert JC, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1094–9.

    Article  CAS  PubMed  Google Scholar 

  51. Foster EM, et al. Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Front Neurosci. 2019;13:164.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Rahman MM, Lendel C. Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology. Mol Neurodegener. 2021;16(1):59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Chung J, et al. Genome-wide association study of Alzheimer’s disease endophenotypes at prediagnosis stages. Alzheimers Dement. 2018;14(5):623–33.

    Article  PubMed  Google Scholar 

  54. Wojtas AM, et al. Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. Proc Natl Acad Sci U S A. 2017;114(33):E6962-e6971.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Chen F, et al. Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology. Mol Neurodegener. 2021;16(1):5.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Singh N, et al. BACE-1 inhibition facilitates the transition from homeostatic microglia to DAM-1. Sci Adv. 2022;8(24):eabo1286.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Singh N, et al. Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance. Sci Adv. 2022;8(29):eabo3610.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Holt LM, Olsen ML. Novel Applications of Magnetic Cell Sorting to Analyze Cell-Type Specific Gene and Protein Expression in the Central Nervous System. PLoS One. 2016;11(2):e0150290.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Chen X, et al. Jagged1 expression regulated by Notch3 and Wnt/beta-catenin signaling pathways in ovarian cancer. Oncotarget. 2010;1(3):210–8.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Schildge S, et al. Isolation and culture of mouse cortical astrocytes. J Vis Exp. 2013;71:50079.

    Google Scholar 

  61. Li X, et al. Mechanisms of transthyretin inhibition of β-amyloid aggregation in vitro. J Neurosci. 2013;33(50):19423–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Kucukdereli H, et al. Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc Natl Acad Sci U S A. 2011;108(32):E440–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Ramamoorthy P, Whim MD. Trafficking and fusion of neuropeptide Y-containing dense-core granules in astrocytes. J Neurosci. 2008;28(51):13815–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Biundo F, et al. Interaction of ApoE3 and ApoE4 isoforms with an ITM2b/BRI2 mutation linked to the Alzheimer disease-like Danish dementia: Effects on learning and memory. Neurobiol Learn Mem. 2015;126:18–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Westwood AJ, et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 2014;82(18):1613–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Klein DM, Felsenstein KM, Brenneman DE. Cathepsins B and L differentially regulate amyloid precursor protein processing. J Pharmacol Exp Ther. 2009;328(3):813–21.

    Article  CAS  PubMed  Google Scholar 

  67. Kang MJ, et al. Caveolin-1 upregulation in senescent neurons alters amyloid precursor protein processing. Exp Mol Med. 2006;38(2):126–33.

    Article  CAS  PubMed  Google Scholar 

  68. Wang S, et al. Synapsin-caveolin-1 gene therapy preserves neuronal and synaptic morphology and prevents neurodegeneration in a mouse model of AD. Mol Ther Methods Clin Dev. 2021;21:434–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Agbemenyah HY, et al. Insulin growth factor binding protein 7 is a novel target to treat dementia. Neurobiol Dis. 2014;62:135–43.

    Article  CAS  PubMed  Google Scholar 

  70. Wei R, et al. ceRNA Network Analysis Reveals AP-1 Tanscription Factor Components as Potential Biomarkers for Alzheimer’s Disease. Curr Alzheimer Res. 2022;19(5):387–406.

    Article  CAS  PubMed  Google Scholar 

  71. Iliff JJ, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4(147):147ra111.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Oh SB, et al. Clusterin contributes to early stage of Alzheimer’s disease pathogenesis. Brain Pathol. 2019;29(2):217–31.

    Article  CAS  PubMed  Google Scholar 

  73. Hoe HS, et al. The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J Neurosci. 2007;27(40):10895–905.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


We also want to thank JAX single cell core facility and the Bioinformatics Core at UConn Health for the support of this study. Full blots of immunoblot experiments can be found in supplemental materials. These shared services are supported in part by the JAX Cancer Center (P30 CA034196).


Riqiang Yan is supported by grants RF1AG058261, AG025493, NS074256, and AG046929 from the National Institutes of Health. Dr. Yan’s lab is also supported by the Cure Alzheimer’s Fund.

Author information

Authors and Affiliations



JZ designed and conducted experiments, wrote the draft: NJ supports the analysis of RNA-seq results; JG and JH conducted partial experiments; XH helped data analysis; RY supervised the project and wrote the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Riqiang Yan.

Ethics declarations

Ethics approval and consent to participate

All experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Connecticut School of Medicine in compliance with the guidelines established by the Public Health Service Guide for the Care and Use of Laboratory Animals.

Consent for publication

All authors have read and approved the final manuscript.

Competing interests

All authors declare no conflict of interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplemental Figure S1.

Quality control measure of Bace1-/- and Bace1+/+ scRNAseq. (A) Violin plots of data set quality control measurement for nFeature_RNA, nCount_RNA, and generated from each ACSA2+-enriched sample. Samples 1a, 2a, 3a are from Bace1+/+ mice, while samples 4a, 5a, 6a are from Bace1-/-. Filtered cutoff points were set at GEMS containing >1,000 identified genes, <25,000 read counts, and <20% mitochondrial RNA. (B) Visualization of UMAP dimension plot with identified cell type clusters from Bace1-/- and Bace1+/+ scRNAseq. R Astrocytes refers reactive astrocytes, and OPC stands for oligodendrocyte precursor cells. The visible difference is the increase in the R Astrocyte cluster in Bace1-/- samples. Supplemental Figure S2. Quality control measure of 5xFAD;Bace1fl/fl;UBC-creER and 5xFAD;Bace1fl/fl. Quality control measured for nFeature_RNA, nCount_RNA, and generated from pooled ACSA2+-enriched samples from 5xFAD;Bace1fl/fl;UBC-creER (Sample 1A) and 5xFAD;Bace1fl/fl (Sample 3a) Filtered cutoff points were set at GEMS containing >1,000 identified genes, <25,000 read counts, and <20% mitochondrial RNA. Supplemental Figure S3. Validation of siRNA Clu knockdown. (A) Western blot of WT primary astrocytes treated with either 80, 40, 20, 10 pmol of Clu siRNA or 80 pmol of control scrambled siRNA. Images indicate major bands for CLU and actin. (B) CLU band intensity normalized to actin. We noted that 80 pmol of Clu siRNA resulted in an approximately 50% decrease in LU levels compared to control siRNA. Supplemental Figure S4. Targeted astrocytic deletion of Bace1 increases Aβ clearance. Representative images from Thioflavin-S staining of amyloid plaques from fixed saggital brain sections of 5xFAD;Bace1fl/fl;Gfap-cre and 5xFAD;Bace1fl/fl. Insets highlight hippocampal and cortical regions that are presented in Fig. 9A. Supplemental Table 1. List of differentially expressed genes of Bace1-/- reactive astrocytes. Supplemental Table 2. List of differentially expressed genes of 5xFAD;Bace1fl/fl;UBC-creER reactive astrocytes.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, J., Singh, N., Galske, J. et al. BACE1 regulates expression of Clusterin in astrocytes for enhancing clearance of β-amyloid peptides. Mol Neurodegeneration 18, 31 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • BACE1
  • Amyloid plaques
  • Reactive astrocytes
  • Clusterin
  • CXCL14
  • Insulin receptor
  • Aβ clearance